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Running title: Effects induced by a sensitization regime of MDPV 
ABSTRACT    
3,4-methylenedioxypyrovalerone (MDPV) is a synthetic cathinone with cocaine-like properties. 
In a previous work, we exposed adolescent mice to MDPV, finding sensitization to cocaine 
effects, and a higher vulnerability to cocaine abuse in adulthood. Here we sought to determine if 
such MDPV schedule induces additional behavioral-neuronal changes that could explain such 
results.  
After MDPV treatment (1.5 mg·kg
-1
, twice daily, 7 days), mice were behaviorally tested. Also, 
we investigated protein changes in various brain regions 
MDPV induced aggressiveness and anxiety, but also contributed to a faster habituation to the 
open field. This feature co-occurred with an induction of ΔFosB in the orbitofrontal cortex that 
was higher than its expression in the ventral striatum.  
Early after treatment, D2R:D1R ratio pointed to a preponderance of D1R but, upon withdrawal, 
the ratio recovered.  Increased expression of Arc, CDK5 and TH, and decrease in DAT protein 
levels persisted longer after withdrawal, pointing to a neuroplastic lasting effect similar to that 
involved in cocaine addiction. The implication of the hyperdopaminergic condition in the 
MDPV-induced aggressiveness cannot be ruled out.  We also found an initial oxidative effect of 
MDPV, without glial activation. Moreover, although initially the dopaminergic signal induced 
by MDPV resulted in increased ΔFosB, we did not observe any change in NFκB or GluA2 
expression. 
Finally, the changes observed after MDPV treatment could not be explained according to the 
autoregulatory loop between ΔFosB and the epigenetic repressor G9a described for cocaine. 
This provides new knowledge about the neuroadaptive changes involved in the vulnerability to 
psychostimulant addiction. 
*Manuscript




 Adolescent mice treated with MDPV were tested at early and late withdrawal 
 MDPV group showed increased entries to center in the open field test 
 The rise in cortical ΔFosB by MDPV correlates with this risky behavior  
 MDPV induced lasting overexpression of Arc, CDK5 and changes in dopaminergic status  
 24h after treatment, oxidative markers and G9a N-methyltransferase were increased 
 
KEYWORDS: MDPV; Adolescent mice; Sensitization, Cocaine, Transcription factors, 
Dopamine  
 
NON-STANDARD ABBREVIATIONS:  
4-HNE, 4-hydroxy-2-nonenal; 




CDK5, cyclin-dependent kinase-5; 
DA, dopamine; 
DAT, Dopamine transporter (DAT); 
DR1, dopamine 1 receptor; 
DR2, dopamine 2 receptor; 
DS, dorsal striatum; 
EPM, elevated plus maze; 
G9a, G9a methyltransferase; 
GFAP, glial fibrillary acidic protein; 
GluA2, AMPA glutamate receptor A2 subunit;  
MDPV, 3,4-methylene-dioxy-pyrovalerone; 
OF, open field; 
OFC, orbitofrontal cortex; 
PVDF, polyvinilidene fluoride sheets; 
RIT, resident intruder test; 
VS, ventral striatum, including NAcc; 
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W1, 1 day after the end of the treatment; 
W2, 2 days after the end of the treatment; 
W3, 3 days after the end of the treatment; 
W21, 21 days after the end of the treatment, is the end of the withdrawal. 
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1. INTRODUCTION 
Synthetic cathinones (i.e. mephedrone, methylone and MDPV, etc) are used as substitutes for 
other stimulants such as amphetamines, cocaine or ecstasy. Among them, pyrrolidine 
derivatives such as 3,4-methylenedioxypyrovalerone (MDPV) are more lipophilic and more 
able to cross the blood–brain barrier. MDPV shows cocaine-like properties and selectively 
inhibits dopamine (DAT) and noradrenaline transporters, being 10- to 50-fold more potent than 
cocaine as a DAT blocker (Baumann et al., 2013; Simmler et al., 2013). Some authors found 
that MDPV has powerful rewarding and reinforcing effects relative to cocaine at one-tenth 
doses, suggesting  that this drug has significant abuse risk based on its potency and subjectively 
positive effects (Aarde et al., 2013; Watterson et al., 2012).  
Repeated administration of psychostimulants induces psychomotor sensitization in rodents. This 
phenomenon has been proposed as a model of an initial stage of psychostimulant addiction in 
humans and it contributes to drug craving (Kalivas and Stewart, 1991; Robinson and Berridge, 
1993). In a previous work, after a twice-daily administration of a moderate dose of MDPV to 
adolescent mice during 7 days, we found a significant sensitization to cathinone locomotor 
effects. In the present work, we tested if repeated exposure to MDPV elicited a distinct behavior 
during withdrawal. With this purpose we evaluated anxiety, habituation and aggressiveness 
using the elevated plus maze (EPM), the open field (OF) and the resident intruder test (RIT) 
paradigms, respectively.  
Cocaine exposure triggers complex adaptations in the brain that are mediated by dynamic 
patterns of gene expression, which are further translated into enduring changes (Schmidt et al., 
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2013). The purpose of the present study was also to evaluate changes in specific neuronal 
biomarkers after a sensitization regime of MDPV that could explain such increase of cocaine 
effects. Also, this knowledge will lead us to a better understanding about the effects of chronic 
MDPV exposure and its neurotoxicological potential. 
In the ventral striatum (VS), we mostly focused on ΔFosB pathway, which is triggered by 
dopamine 1 receptor (DR1) and p-CREB signaling. We also studied related markers including 
cyclin-dependent kinase-5 (CDK5), GluA2, an AMPA glutamate receptor subunit, nuclear 
factor kappa B (NFκB) and activity-regulated cytoskeleton-associated protein (Arc). To be 
activated, CDK5 has to associate with its regulatory subunit, p35, both regulated by ΔFosB 
(McClung et al., 2004; Nikolic et al., 1996). The p35/CDK5 is a neuroplasticity mediator, which 
is required for neurite growth (Patrick et al., 1999). On the contrary, p25, a proteolytic fragment 
of p35, causes dysregulation of CDK5 kinase activity. Furthermore, the complex p25/CDK5 
hyperphosphorylates tau, which reduces tau's ability to associate with microtubules (Kelz et al., 
1999)  when CDK5 is activated by p35, it takes part in physiological processes as 
neuroplasticity, while CDK5/p25 and Cdk5/p29 are related with neurotoxic and 
neurodegenerative processes. Arc is an early gene which is rapidly induced by cocaine.  GluA2 
is also a target gene of ΔFosB, but its expression is also under homeostatic regulation as well as 
its surface/intracellular ratio. (Boudreau et al., 2007). Finally, we also determined G9a a 
histone-lysine N-methyltransferase, because it is considered an important control mechanism for 
epigenetic regulation during the development of cocaine addiction state (Maze et al., 2010). 
In the dorsal striatum (DS) we measured the expression of parameters related with 
dopaminergic neurotransmission. Repeated exposure to classical psychostimulants also induces 
various synaptic adaptations, many of them related to sensitization and neuroplastic processes 
including up- or down-regulation of DR1 (RRID:RGD_10412325) and DR2 
(RRID:IMSR_RBRC02332), changes in subunits of G proteins, increased adenylyl cyclase 
activity and increased tyrosine hydroxylase enzyme (TH) activity or dopamine (DA) transport 
(Bibb et al., 2001). Accordingly TH, DAT, DR1 and DR2 levels, as well as lipid peroxidation 
were assessed following MDPV exposure. Lipid peroxidation is one of the major sources of free 
radical–mediated injury that directly damages membranes and generates a number of secondary 
products. Following lipid peroxidation, 4-hydroxy-2-nonenal (HNE) is one of the most 
abundant resulting products. Therefore, 4-HNE is considered a robust marker of oxidative stress 
and a toxic compound for several cell types (Perluigi et al., 2012). Its assessment, jointly with 
that of GFAP, provided information about a putative neurotoxic effect of MDPV.  
Some data indicate that the induction of ΔFosB within the OFC plays a role in the deficit in 
impulse control mediated by cocaine (Winstanley et al., 2009). For this reason and in view of 
the results obtained in the OF, we also assessed the induction of ΔFosB in this cortical area. 
2. MATERIALS AND METHODS 
2.1. Animals 
All animal care and experimental protocols in this study were approved by the Animal Ethics 
Committee of the University of Barcelona, under the supervision of the Autonomic Government 
of Catalonia, and are in accordance with the United States Public Health Service Guide for the 
Care and Use of Laboratory Animals and with European Community Council Directive 
(2010/63/EU for animal experiments). All efforts were made to minimize animal suffering and 
to reduce the number of animals used. Animal studies are reported in compliance with the 
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ARRIVE guidelines. CD-1 mouse strain was selected for its optimal sensitivity to the 
reinforcing and psychostimulant effects of cocaine (McKerchar et al., 2005). Animals were 
housed six per cage (polycarbonate with wood-derived bedding) at 22 ± 1 ºC under a 12 h 
light/dark cycle with free access to food and drinking water. Male Swiss CD-1 mice (Charles 
River, Spain) at the beginning of periadolescence (PND 41-44) were used.  
2.2. Materials 
Pure racemic MDPV · HCl was synthesized and characterized in our laboratory as previously 
described (Novellas et al., 2005). Cocaine was provided by the Spanish National Institute of 
Toxicology. Both MDPV and cocaine solutions were prepared in 0.9% NaCl (saline, pH=7.4) 
immediately before administration.  
The protease and phosphatase inhibitors cocktail was purchased from Abcam (Cambridge, UK). 
BS
3 
[bis(sulfosuccinimidyl)suberate] was from ThermoFisher Scientific (Rockford, USA) and 
[
3
H]WIN 35428 was from Perkin Elmer (Boston,  USA). All the other reagents were of 
analytical grade and purchased from several commercial sources. 
2.3. Drug administration protocol and experimental design 
Mice were treated with MDPV (1.5 mg·kg
-1
, s.c.) or saline (5 ml·kg-1 s.c.), two doses in one 
day (4 h apart), for seven consecutive days, and housed in their cages until reaching adulthood 
(PND 69-72, 21 days). Behavioral tests including resident-intruder test (RIT), elevated plus 
maze (EPM) and the open field (OF) paradigms were performed during withdrawal as described 
below (Fig. 1A). Different lots of animals were used for biochemical and behavioral 
experiments. Doses of drugs and treatment schedules are based on our previous study (López-
Arnau et al., 2017). 
 
2.4. Elevated plus maze (EPM) 
Either 48h (W2) or 21 days (W21) after treatment, the anxiety-related behavior was measured 
using the EPM paradigm. Briefly, the maze was elevated 42 cm above the ground and consisted 
of two open and two closed arms (30 x 6 cm) which radiated from a central platform (6 x 6 cm). 
Testing was conducted under low room lighting conditions (30 LUX). The mice were placed on 
the center, facing an open arm, an allowed to explore for 5 min.-The behavior was recorded by a 
zenithal camera connected to a computerized tracking system (Smart 3.0 software, PanLab SL, 
Spain). The time spent in the center of the maze was discarded and the results are expressed as 
the total time spent in closed and open arms. 
2.5. Open field (OF) 
Either 3(W3) or 21 days (W21) after the end of the treatment, the same mice were evaluated in a 
circular open arena sized 100 cm in diameter. Previously, mice underwent two consecutive 
habituation sessions (10 min, days W1 and W2). The floor of the circular arena was virtually 
divided into two zones, namely the center (70 cm) and the periphery. The time spent in these 
two defined zones was recorded during 10 min with the same computerized system cited above. 
Results are expressed as the fraction of total exploratory time spent in the central zone, as well 
as other parameters like the number of entries in center, the latency of the first entrance to the 
center, central vs. total walking ratio, locomotion and mean speed of animals. 
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2.6. Resident intruder test (RIT) 
Mice were tested for offensive aggressive behavior using the resident-intruder paradigm either 
one (W1) or 21 days (W21) post-treatment, as described (Koolhaas et al., 2013).  Briefly, each 
mouse (resident) was housed with a female for at least one week before the test day. This fact 
facilitated the development of territoriality and prevented social isolation. The females were 
previously sterilized by ligation of the oviducts, so they were regularly receptive without 
becoming pregnant and developing maternal aggression. On the experiment day, the female was 
removed from the residential cage one hour before the test and an unfamiliar male (intruder) 
was introduced into the home cage. The resident-intruder interactions were video-recorded for 
10 min and the resident was scored for two general measures of offensive aggression: latency to 
the first attack and number of attacks. If any signs of suffering or wounds were observed, the 
animals were immediately separated, and the experiment was terminated. However, no early 
ending was required in any case.  
2.7. Tissue sample preparations 
Mice were killed by cervical dislocation 2 h (Day 7) or 24 h after the treatment (Day 8, W1), as 
well as 21 days after treatment (Day 28, W21), for the analysis of several factors including Arc, 
GluA2, CDK5, p35/p25, phospho-Tau (Thr205)/Tau, NFκB, G9a, TH, DAT, D1R, D2R, 
ΔFosB, 4-HNE and glial fibrillary acidic protein (GFAP). Orbitofrontal cortex (OFC) and VS 
(including NAcc) or DS, when appropriate, were quickly dissected out and stored at -80ºC until 
use. Particularly, for the dissection of the OFC, brains were rapidly removed and placed in a 
mouse brain acrylic matrix (Alto, Agnthos, Sweden) placed on ice. Two double edge blades 
were used to obtain a 1 mm thick slice (from 2 to 3 mm anterior to bregma), that contains the 
region of interest. The anatomical boundaries for each brain subregion are depicted in Fig. 1B 
In order to reduce the number of animals, the VS was used to study the signaling pathways 
related with neuroplasticity and those considered involved in the rewarding and sensitizing 
effects, while the DS was reserved to assess the neuroadaptations that take place in the 
dopaminergic transmission and the possible neurotoxic effects of a repeated exposure to MDPV. 
Tissue samples for Western blot analysis were processed as described (Pubill et al., 2013) with 
minor modifications. Briefly, tissue samples were homogenized at 4 ºC in 20 volumes of lysis 
buffer (20 mM Tris-HCl, pH=8, 1% NP40, 137 mM NaCl, 10% glycerol, 2mM EDTA) with the 
protease inhibitor cocktail. The homogenates were shaken and rolled for 2h at 4 ºC and 
centrifuged at 15,000 x g for 30 min at 4 ºC. Aliquots of resulting supernatants (total lysate) 
were collected and stored at -80 ºC until use. Protein content was determined using the Bio-Rad 
Protein Reagent (Bio Rad, Inc., Spain). 
2.8. Dopamine transporter density 
The density of the DA transporter in striatal membranes was measured using [
3
H]WIN 35428 
binding assays as described previously (López-Arnau et al., 2015). The crude membrane 
preparation used in the experiments collects both the synaptosomal membrane and the 
endosomal fraction. 
 




Total RNA isolation from VS was carried out by means of a TRI reagent-Chloroform based 
extraction protocol. RNA content in the samples was measured at 260 nm, and sample purity 
was determined by the A260/280 ratio in a NanoDrop
TM
 ND-1000 spectrophotometer (Thermo-
Fisher Scientific). The isolated mRNA was reverse-transcribed by a Reverse Transcription 
Polymerase Chain Reaction (RT-PCR) using the High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems) and the Veriti® thermal cycler (Applied Biosystems, Foster, CA, 
USA). Briefly, complementary DNA (cDNA) was synthesized in a total volume of 20 μL by 
mixing 1 μg of total RNA and the appropriate volumes of each reagent.  The cDNA product was 
used for subsequent real-time PCR amplification using the Step One Plus
TM
Real-Time PCR 
System (Aplied Biosystems, USA) with 25 ng of the cDNA mixture and the assays-on-demand 
from Applied Biosystems Mm00479619_g1for Arc, Mm0113261_m1 for G9a and 
Mm00607939_s1 for Actb as an endogenous control. Fold-changes in gene expression were 
calculated using the standard comparative Cycle threshold (Ct) method (ΔΔCt) (Livak and 
Schmittgen, 2001). 
2.10. Surface receptor cross-linking with BS3 
21 days after the last injection of MDPV or saline, mice were killed by cervical dislocation. 
Accumbal tissue from each mouse was processed for cross-linking assays as described 
(Boudreau et al., 2007). 
2.11.  Western blotting and immunodetection 
A general Western Blotting and immunodetection protocol was used. Briefly, for each sample, 
10-25 µg of protein was mixed with sample buffer (0.5M Tris-HCl, pH=6.8, 10% glycerol, 2% 
(w/v) SDS, 5% (v/v) 2-β-mercaptoethanol, 0.05% bromophenol blue), boiled for 5 min and 
loaded onto a 10% acrylamide gel or on a 4-15% gradient Tris-HCl gel (Bio-Rad, Hercules, 
CA) in the case of the surface receptor cross-linking with BS
3
. Proteins were electrophoresed 
and subsequently transferred to polyvinilidene fluoride sheets (PVDF) (Immobilon-P; Millipore, 
USA). PVDF membranes were blocked for 1h at room temperature with 5% defatted milk in 
Tris-buffer plus 0.05% Tween-20 and incubated overnight at 4 ºC with the corresponding 
primary antibodies (Table 2). After washing, membranes were incubated for 1 h at room 
temperature with the corresponding peroxidase-conjugated anti-IgG antibody. Immunoreactive 
protein was visualized using a chemoluminiscence-based detection kit following the 
manufacturer’s protocol (Immobilion Western, Millipore) and a BioRad ChemiDoc XRS gel 
documentation system (BioRad, Inc., Madrid, Spain). Scanned blots were analyzed using a 
BioRad Image Software and dot densities were expressed as a percentage of those taken from 
the control. As a protein load control, immunodetection of β-tubulin (1:2500, Sigma Aldrich) or 
GAPDH (1:5000, Merck Millipore) was used. The whole list of antibodies used in these 
experiments is contained in supplementary material/table1. 
2.12. Data analysis  
Data from biochemical analyses were normalized with 100% defined as the mean of the 
technical replicates in the control group, and the SEM was normalized appropriately. Animals 
were randomly assigned to an experimental group. During the behavioral manipulations, 
researchers were not aware of the pretreatment that each animal previously received.   
Data were expressed as mean ± standard error of the mean (SEM). Differences between groups 
were compared using one or two-way analysis of variance (ANOVA) or Student’s test for 
independent samples where appropriate. Significant differences (p<0.05) were analyzed using 
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the Bonferroni post hoc test for multiple comparison measures only when F achieved the 
necessary level of statistical significance (p<0.05) and there was no significant variance in 
homogeneity. The exact group size for the individual experiments is shown in the corresponding 
figure legends. Statistic calculations were performed using GraphPAD Prism 6.0 software.  
 
 
3. RESULTS  
 
3.1. Effects of MDPV treatment on anxiety, impulsivity and aggression 
 
The EPM test was performed in order to assess anxiogenic or anxiolytic effects induced by drug 
withdrawal. The cathinone derivative did not increase anxiety 48 h after treatment, since both 
the control and the MDPV groups displayed a similar anxious-behavior after a continued 
treatment (saline: open arms 53.90 ± 8.28 s; closed arms: 126.91 ± 10.58 s, t10=3.879 P<0.01; 
MDPV: open arms 41.33 ± 8.62 s; closed arms 121.59 ± 18.30 s, t8=3.023, P<0.05). 
Nevertheless, after 21 days of withdrawal (W21), when EPM was carried out in a different 
batch of animals, the saline group did not show differences between open and closed arms (open 
arms  81.78 ± 13.27 s, closed arms 111.62 ± 8.04 s,  t6= 1.915, n.s), while MDPV-treated mice 
still presented an anxious-behavior, that is, the animals spent significantly more time in the 
closed arms than in the open (open arms 57.16 ± 11.45 s, closed arms 118.38 ± 16.85 s, t7= 
2.315, P=0.05)) (Fig. 2B). Two-way ANOVA analysis of the time spent in the open arms, 
which is the main parameter measuring anxiety-like behavior, revealed a significant effect of 
treatment (F1,33=4.280, P=0.0465), with lower values in the MDPV group, and also of time 
(F1,33= 5.429, P=0.0261)(W2: saline n=11 and MDPV n=9; W21: saline n=7 and MDPV 
n=8)(Fig. 2A).  
In the OF, the behavior of both groups started to diverge until reaching statistical significance 
on day W21 (Fig. 2B; two-way ANOVA: variable treatment F1,13=5.687, P=0.0330, variable 
time F1,13=34.560 P=0001; interaction F1,13=5.974, P=0.0295; saline n=7 and MDPV n=8). 
Specifically, MDPV-treated mice spent more time in the central area of the arena, considered 
aversive, compared with the control group, aside from exhibiting a more central vs. total 
walking ratio, a shorter latency in the first entrance to the center, and a higher but not significant 
number of entries in the center (Fig. 2B, Table 1). Overall, there were no significant differences 
between MDPV and saline-treated mice regarding to the speed and total distance travelled in 
every trial (Table 1). 
Increased aggressiveness was demonstrated in the RIT. Two-way ANOVA analysis of the 
latency to the first attack showed a significant effect of variable treatment (F1,17= 4.456, 
P=0.0499) and withdrawal time (F1,17= 7.303, P=0.0151). The same statistical analysis applied 
to the number of attacks exhibited a significant dependence of the variable withdrawal time 
(F1,17=8.215, P=0.0107) and the interaction treatment x time (F1,17= 10.730, P=0.0045) 
(saline n=9 and MDPV n=10). Post-hoc analysis indicated that adolescent mice of MDPV 
group, at W1, showed a shorter latency time to first attack than saline group. Aggressive 
behavior was also supported by the fact that the attacks by MDPV-treated mice were much 
more frequent (Fig. 2C, 2D). When this behavior was re-evaluated 21 days after, when the 
animals had already reached adulthood, the saline group showed a shorter latency to first attack 
than the adolescent, probably due to the fact that adults show a greater territorial behavior. 
However, the number of attacks of the MDPV group at W21 did not differ from that of saline. 
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Therefore, MDPV only increased aggressive behavior when tested shortly after exposure, an 
effect that disappeared after the long withdrawal.  
3.2. Transcriptional mechanisms activated after a chronic exposure to MDPV 
Once the treatment with MDPV was finished, the expression of several factors in the striatum 
was determined by Western blot, qPCR and radioligand binding assays.  
3.2.1. Expression of factors related to neuroplasticity, sensitizing and reinforcing 
effects in the ventral striatum (including NAcc)   
Arc levels were determined in the striatum 2 h after the treatment with MDPV, showing a 
significant increase compared with the saline group (t10=2,567, P=0.0280, n=6 per group) (Fig. 
3A). Interestingly, the Arc expression decreased after MDPV withdrawal (t8=2.71, P=0.0254, 
n=5 per group) (Fig. 3B). Due to this unexpected result, the mRNA levels encoding Arc were 
quantified by qPCR in the VS of saline and MDPV-treated mice, on W21. MDPV-mice 
presented significantly higher levels (37%) of Arc mRNA (Fig. 3B, inset)(t12=2.281, P=0.0416, 
saline n=8 and MDPV n=6). 
On the other hand, some of the validated target genes for ΔFosB in nucleus accumbens, such as 
CDK5, GluA2, and NFκB, were assayed. Additionally to the higher levels of ΔFosB, W1 
MDPV-treated mice showed a significant increase of 29% in CDK5 expression (t10= 4.783, 
P=0.0007, n=6 per group) (Fig.3C). However, this increase was not accompanied by a 
pathological activation of the protein as the ratio p35/p25 did not show significant differences 
between the groups of treatment (t10 =0,276, n.s.; n=6 per group). Accordingly, the levels of 
phospho-Tau (Thr205)/Tau were not altered by MDPV exposure (t10 =1,192, n.s., n=6 per 
group) (Fig. 3E and 3F).  Moreover, a 29% increase in CDK5 levels was also found after the 
MDPV withdrawal (W21) (t8=1.871, P=0.0492, n=5 per group) (Fig. 3D). This increase was the 
same as that seen 24h post-treatment, suggesting a stable overexpression of this factor during 
the withdrawal. 
Another ΔFosB target assayed was NFκB. In VS this factor remained unaffected just after 
treatment with MDPV (saline: 100 ± 4.78%; MDPV: 101.51 ± 5.29%, t10= 0.212, n.s., n=6 per 
group).  
No change in GluA2 expression was detected in VS at W1 (saline: 100 ± 8.74%; MDPV: 
106.70 ± 14.16%, t10= 0.402, n.s., n=6 per group). However, on W21, the levels were halved (t8 
=3.090, P=0.0149, saline n=5 and MDPV n=4). At this time, an apparent internalization of this 
subunit was obtained, although it did not reach statistical significance (t10= 1.817, n.s., n=6 per 
group) (Fig. 3G and 3H). 
We also determined G9a expression through quantification of mRNA encoding G9a gene in 
VS, 24 h after repeated MDPV exposure. Surprisingly, the results showed a significant increase 
in G9a transcription in the MDPV group (t8=4.229, P=0.0029, n=5 per group) (Fig. 4). 
3.2.2.  Expression of factors related with dopaminergic transmission in the dorsal 
striatum  
The levels of D1R were significantly increased in MDPV-treated mice 24h after the treatment 
(t10=3.289, P=0.0082, n=6 per group) (Fig. 5A). Also, as reported previously, D2R levels were 
significantly lower in MDPV mice (saline: 100 ± 7.68%, MDPV: 73.70 ± 6.59%), therefore, the 
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ratio D2R:D1R points to a preponderance of D1R. After the withdrawal (W21) the MDPV 
group showed a significant decrease of around 25% in the population of D1R, (t8= 2.931, 
P=0.0190, n=5 per group) (Fig. 5B), while D2R levels remained stable (data not shown). 
Therefore, the D2R:D1R ratio changed again. 
TH, the key enzyme for the biosynthesis of DA, was up-regulated 24h after dosing (t10=2,573, 
P=0.0277, n=6 per group) and its overexpression persisted during withdrawal (t8=2.316, 
P=0.0492, saline n=5 and MDPV n=5) (Fig. 5C and 5D). 
Finally, we measured the levels of [
3
H]WIN 35428 bound to a crude membrane preparation of 
the striatum, as a marker of DAT in dopaminergic terminals. No changes were observed in DAT 
shortly after MDPV exposure (W1) (t9= 0.355, n.s., saline n=5 and MDPV n=6). However, 
when binding was assessed after withdrawal (W21) DAT levels were significantly decreased 
(t14= 2.484, P=0.0264, n=8 per group) (Fig. 5E and 5F).  
3.3. Neurotoxic effects of MDPV in dorsal striatum 
In order to assess any possible neurotoxic effect of the repeated exposure to the drug, 4-HNE, a 
marker of lipid peroxidation, and GFAP were measured. 24h after treatment, 4-HNE increased 
by almost 200% (Saline: 100 ± 19%; MDPV: 296.51 ± 35.16 %, t10=4.889, P=0.0006, n=6 per 
group) possibly due to the synaptic oxidation of DA and quinones formation, while no changes 
were observed in GFAP expression (Saline: 100 ± 14%; MDPV: 100.89 ± 13.13%, t10=0,046, 
n.s., n=6 per group). Considering these results, we also assessed the levels of the same markers 
at W21, since the GFAP response could be delayed in time. The expression of this glial protein, 
however, remained unaltered (saline: 100 ± 27.78 %; MDPV: 92.42 ± 16.84 %, t8= 0.233, n.s., 
n=5 per group). On the other hand, 4-HNE levels decreased to be non-significantly different 
from saline group (saline: 100 ± 9.06 %; MDPV: 84.77 ± 5.62 %, t10= 1.429, n.s., n=6 per 
group), suggesting a transient pro-oxidative effect of MDPV.   
3.4. Effects of MDPV treatment on ΔFosB expression in the orbitofrontal cortex after 
withdrawal  
Some data indicate that the induction of ΔFosB within the OFC plays a key role in the deficit in 
impulse control mediated by cocaine (Winstanley et al., 2009). In light of our results in the OF 
paradigm, we determined how the MDPV treatment might have altered the expression of this 
transcription factor in the OFC at the same time point we had evidenced significant differences 
in the OF paradigm, (W21). In this area, MDPV induced a significant increase of ΔFosB 
expression (saline: 100 ± 19.65%; MDPV: 175.76 ± 15.84%, t9==3.04, P=0.0140; saline n=5 per 
group and MDPV n=6 per group).  
4. DISCUSSION    
In the present work, we studied the behavioral and neuroadaptive changes induced by a 
sensitizing MDPV exposure. The most important results from the behavioral experiments are 
the long-lasting anxiogenic effect, the increase in high risk-taking behavior and the 
aggressiveness evidenced shortly after the MDPV treatment. At the same time, MDPV triggers 





Initially, the animals were evaluated for anxiety, habituation and aggressiveness using the EPM, 
OF and RIT paradigms, respectively. Regarding to the EPM, the repeated exposure to MDPV 
caused an anxiogenic effect (more time in the closed arms) that is apparent mainly long after 
treatment, when animals have become adults.  
The anxiogenesis displayed by the animals treated with the cathinone derivative suggests 
changes in other behavioral issues. A simple way to observe these changes is in the OF, so we 
proceeded to assess various parameters of mice activity in this paradigm, which provides an 
initial screen for emotional-related behavior (Bailey and Crawley, 2009). After habituation (W3, 
W21), MDPV-treated mice ventured more frequently into the central area, so permanence in the 
center increased without changing the pattern of locomotor activity or the mean speed. The time 
spent in the center area in the OF involves leaving a defensive zone to enter in a more exposed 
zone, so it can be interpreted as a faster habituation to the new environment favoring this risky 
behavior (Clément et al., 1995). It cannot be attributed to an anxiolytic effect, because actually, 
in the EPM paradigm, MDPV has rather the opposite effect. This particular pattern of behavior 
in the OF is also observed some days after ending a long-term treatment with MDMA (Abad et 
al., 2013; Mechan et al., 2002), although, as it occurs with MDPV, exposure to MDMA induced 
a lasting anxiogenic response in the EPM (Rodríguez-Arias et al., 2011). Repeated exposure to 
the OF test, as in our experiments, provides a method for assessing habituation to the 
increasingly familiar chamber environment. After repeated exposure to MDMA or MDPV, 
animals adapt faster to the repeated social isolation resulting from the physical separation from 
cage mates when performing the OF test, and the stress created by the brightly lit, unprotected 
novel test environment.  
In addition to the effect of MDPV on anxiety and habituation, we assessed aggressiveness. 
Based on case studies, MDPV, as other cathinone derivatives, tends to produce increased 
aggressive behavior (James et al., 2011; Murray et al., 2012; Penders et al., 2012). In our study 
we evidenced that territorial aggression was increased in the MDPV group when it was tested 
shortly after the treatment. This is the first time in the literature reporting that MDPV exposure 
can increase the aggressive behavior in mice.  In humans, it is suggested a role of the D2 
receptors in pathological aggressive behavior. Chen et al. (2005) observed a correlation between 
the dopamine D2 receptor gene and DAT gene polymorphisms with pathological violence in 
adolescents, in a blinded clinical trial, linking hypo-activation of striatal and prefrontal areas to 
disease severity. Therefore, we cannot rule out the possibility that the changes in dopaminergic 
neurotransmission evidenced early after MDPV exposure could contribute to the aggressiveness 
induced by MDPV. This behavioral effect declined upon withdrawal, when the D2/D1 ratio 
recovered and synaptic DA clearance by DAT was reduced. 
Another purpose of the present study was to investigate changes in specific neuronal biomarkers 
after a sensitization regime of MDPV, which could explain the increased sensibility to cocaine 
effects long after MDPV exposure. In this sense, the activation of immediate early genes, such 
as Arc, by psychomotor stimulants has been interpreted primarily as a key step influencing long-
term plasticity in neurons (Nestler, 2001). In our study, MDPV-treated mice showed an early 
increase of Arc protein levels, which significantly reversed after withdrawal. After this result we 
wanted to find an explanation for this decline, measuring the expression of the gene encoding 
Arc. The observed discrepancy between Arc mRNA and protein levels under these 
circumstances was also described for cocaine (Fumagalli et al., 2006), and it was attributed to a 
reduced Arc mRNA turnover or to an inhibition of protein synthesis. However, we cannot rule 
out that the accompanying increase in protein could not be detected because the protein had 
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been specifically targeted to dendrites/synapses after long stimulation periods. Our results 
regarding Arc are relevant, as this protein is considered a reliable index of activity-dependent 
synaptic modifications (Larsen et al., 2005), and its overexpression was also reported after 
chronic cocaine treatment (Fumagalli et al., 2006). In this sense, Arc has also been associated to 
altered morphology of dendrites and spines observed after this drug exposure. In this sense, our 
results suggest that there is a high probability that the repeated treatment with MDPV also 
causes a structural modification of these neuronal elements. 
As previously reported (López-Arnau et al., 2017), repeated exposure of adolescent mice to 
MDPV increases ΔFosB expression in the VS 24 h after ending the treatment (≈ 290%) and, 
although it declined during the 21 days of withdrawal, this factor remained increased (≈ 135%). 
Additionally, we measured ΔFosB in OFC, because a relationship between its overexpression in 
this brain area and an increase in risk-taking behavior and locomotor sensitization to cocaine has 
been demonstrated (Winstanley et al., 2009). In our study, the animals that received MDPV 
showed an increase of ΔFosB in the OFC of about 75% after withdrawal which is, in fact, more 
than double of that registered in the VS. Therefore, the sensitization of MDPV-treated animals 
to the locomotor-psychostimulant properties of cocaine is associated to increased levels of 
ΔFosB in the VS and the OFC, with this latter area showing a much higher increase. 
Accordingly, we cannot rule out that the changes in ΔFosB in both areas contribute to the 
increased sensitivity to this psychostimulant. 
It is known that ΔFosB is involved in close to one quarter of all the genes influenced by chronic 
cocaine exposure in the NAcc and it functions primarily as a transcriptional activator or as a 
repressor, depending on the duration and the degree of its expression (Nestler, 2008). CDK5 is 
also an example of a gene that is induced by chronic, but not acute, cocaine administration 
(Bibb et al., 2001) and the activation of CDK5 is not only under positive control of ΔFosB but is 
also regulated by extracellular signal-regulated kinase (ERK) whose phosphorylation is 
increased in the NAcc by drugs of abuse through a dopamine D1 receptor-dependent 
mechanism (Valjent et al., 2004). In our experiments, MDPV-treated mice showed a significant 
increase in CDK5 levels, and this overexpression was still apparent after 3 weeks of withdrawal, 
even in the same percentage. Thus, unlike ΔFosB, which declined over time, the expression of 
CDK5 remained stable during the whole experiment. Therefore, we cannot rule out that the 
hyperdopaminergic state observed in mice after repeated doses of MDPV activates the 
MAPK/ERK pathway that contributes to the stable effect of the CDK5. 
 
On the other hand, it is known that CDK5 controls dopamine neurotransmission through the 
regulation of DARPP-32, a protein phosphatase-1 inhibitor. In this way, CDK5 mediates 
cellular responses to cocaine-induced changes in dopamine signal transduction and cytoskeletal 
reorganization (Bibb et al., 2001). Therefore, this kinase is also a key element for the plasticity 
observed after the chronic administration of cocaine. Benavides and Bibb (2004) suggested a 
model of cellular signalling pathways under control of CDK5, whose activation takes place 
downstream of the overactivation of D1 receptors after cocaine administration. Given that 
MDPV has the same pharmacological mechanism of action, we might expect a similar chain of 
events to those suggested for cocaine under control of CDK5. Moreover, we also wanted to 
investigate if CDK5 activation could also lead to an abnormal phosphorylation of the TAU 
protein, whose consequences are well known. Although MDPV-treated mice showed increased 
levels of CDK5, when the p35/p25 and phosphor-Tau (Thr205)/Tau ratios were measured no 
differences between groups were found. Moreover, the levels of p35 were much higher than 
p25, suggesting an activation of CDK5.  
13 
 
ΔFosB also regulates the AMPA receptor GluA2 subunit (Kelz et al., 1999; McClung and 
Nestler, 2003). GluA2-containing AMPARs are downregulated after prolonged withdrawal (35-
49 days) from cocaine self-administration leading to an internalization of this subunit (Boudreau 
et al., 2007), but not after prolonged withdrawal from no contingent cocaine injections. In the 
present study, repeated non-contingent administration of MDPV did not produce any acute 
effect on AMPA receptors but, during withdrawal, the adaptive changes produced a very 
significant decrease of the GluA2 subunit. We may speculate that this adaptation of the AMPA 
receptor is the result of an increased glutamatergic neurotransmission, as described for cocaine 
(for review see Vandershuren and Kalivas 2000). Likewise, the glutamate system has been 
associated with the reinforcing and psychostimulant properties of MDPV (Gregg et al, 2016). 
 
In this study we also investigated the influence of epigenetic changes induced by MDPV, as 
these effects have already been described for cocaine. Epigenetic changes have been revealed as 
critical mechanisms contributing to drug-induced plasticity by regulating gene expression. G9a 
specifically catalyzes the demethylation of lysine 9 of histone 3(H3K9me2). Maze et al (2010) 
showed that acute cocaine increases G9a levels in the NAcc. In contrast, they found a down-
regulation of G9a 24 h after repeated cocaine administration consistent with an overexpression 
of some target genes such as Arc (Oey et al., 2015) and ∆FosB (Maze et al., 2010). As ∆FosB 
accumulates, it represses G9a and thereby potentiates its own further induction. In our work, an 
overexpression of this transferase has been observed in the VS 24h after the treatment. Possibly, 
if this repressor transferase was not increased, the overexpression of ∆FosB and Arc would be 
much higher and last longer (as with cocaine). Also, this suggests that another additional factor 
to ∆FosB could modulate the expression of G9a. 
 
Due to MDPV has the same mechanism of action as cocaine, we also studied the evolution of 
parameters related to dopaminergic neurotransmission in the DS. Repeated cocaine exposure led 
to expected short-term changes such as increase of TH expression in NAcc (Rodriguez-Espinosa 
and Fernandez-Espejo, 2015). In parallel, MDPV exposure also increased the expression of TH 
in DS shortly after treatment and 21 days later, suggesting a long-lasting adaptive change in this 
gene expression, probably regulated by several mechanisms (Kumer and Vrana, 1996) as 
CDK5. It is known that increased dopamine uptake through its specific transporter results in 
oxidative damage via the cytosolic oxidation of this neurotransmitter (Masoud et al., 2015). 
Therefore, in the animals that developed a hyperdopaminergic status, the reduction of DAT 
found after MDPV guarantees a resilience response to avoid terminal injury by oxygen radicals 
derived from high DA intracellular levels  
In vivo, chronic cocaine use is accompanied by an immediate change in the D2R:D1R ratio 
signaling towards the D1R (Thompson et al., 2010). In the present study, D1R population 
increased while D2R was reduced in MDPV treated mice. Hence, the D2R:D1R ratio decreased 
approximately by half. However, three weeks post-treatment, the ratio D2R:D1R increased. 
These changes ran in parallel with the increased TH levels and the lower removal of DA from 
synapses via DAT, pointing to an hyperdopaminergic status. All these effects are probably due 
to adaptive neuroplastic changes associated to MDPV abuse and withdrawal. 
Considering that MDPV generates a hyperdopaminergic status, and that high levels of DA can 
cause oxidative reactions, 4-HNE, a robust marker of oxidative stress (Perluigi et al., 2012) and 
GFAP, which indicates glial activation, were assessed to investigate a putative neurotoxic effect 
of the cathinone. Shortly after drug exposure we found that 4-HNE levels had tripled, pointing 
14 
 
to an important oxidative effect generated by DA or by the MDPV metabolism to reactive 
quinones (Baumann et al., 2017). However, after withdrawal, this pathophysiological sign had 
been overcome. On the other hand, GFAP levels remained unaltered the whole time, suggesting 
that this oxidative stress is not severe enough to trigger an astroglial response. These results 
suggest that, although there is significant oxidative effect, it is transient and without relevant 
consequences. 
 
In conclusion, repeated MDPV exposure in mice induces anxiogenic effects and increases 
aggressiveness. We speculate that increased levels of ΔFosB in VS but also in the OFC can 
contribute to locomotor sensitization.  Other signals that persist long after withdrawal probably 
also contribute to the sensitization to MDPV as Arc and CDK5 overexpression, changes in 
D2R/D1R ratio, high levels of TH and a low DA clearance by DAT, pointing to a disorder of 
DA imbalance promoted by MDPV (i.e., long-lasting hyperdopaminergic status). Given that 
MDPV has the same mechanism of action as cocaine, a similar chain of events modulated 
mainly by CDK5 can be hypothesized. Although repeated exposure to MDPV resulted in an 
increase in ΔFosB, as it occurs after cocaine exposure, we did not observe an increase in NFκB 
or GluA2. This may be due to the fact that, in addition to the regulatory autoloop described for 
cocaine between G9a and ΔFosB, there might be other independent regulatory signals 
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Fig 1: (A) Drug administration protocol and experimental design. Animals were treated with 
MDPV or saline two doses in one day (4h apart) during 7 consecutive days. The RIT, EPM and 
OF paradigms were performed 24h (W1, Day 8), 48h (W2, Day 9) and 72h (W3, Day 10) after 
treatment, respectively, as well as after 21 days withdrawal (W21, Day 28). Brain samples were 
collected 2h (Day 7), 24h (W1, Day 8) and 21 days (W21, Day 28) after treatment. (B) 
Schematic diagram that illustrates the dissection of the orbitofrontal cortex (OFC), dorsal 
striatum (DS, nucleus caudate/putamen CPu) and ventral striatum (VS, including nucleus 
accumbens shell and core, AcbSh/AcbC) according to the atlas of Paxinos and Franklin 
(Paxinos and Franklin, 2004). 
Fig 2: Behavioral effects of MDPV treatment. (A) EPM results: Bars represent the time spent in 
the open arms by saline-and MDPV-treated mice in the EPM test 48h and 21 days after 
treatment  (W2: saline n=11 and MDPV n=9; W21: saline = 7, MDPV n=8) (B) OF results: Bars 
represent the time spent by animals in the center of the arena 72h (W3) and 21 days (W21) after 
treatment with MDPV (n=8) or saline (n=7). (C,D) RIT results: Bars represent both the latency 
to the first attack as well as the number of attacks in the RIT after 24h and 21 days of 
withdrawal (saline n=9 and MDPV n=10). Results are expressed as mean ± SEM. #P<0.05 vs 
saline group. 
&
 P<0.05 and 
&&&
P<0.001 W1 vs treatment-matched W21. 
Fig 3: Effect of MDPV treatment on the expression of factors related to neuroplasticity, 
sensitizing and reinforcing effects in VS: (Aa) Arc protein expression 24h (n=6 per group) and 
(b) 21 days after treatment (n=5 per group), as well as on mRNA encoding Arc (saline n=8 and 
MDPV n=6) (B, inset). (C) CDK5 expression 24h (n=6 per group) and (D) 21 days after 
treatment (n=5 per group) (E) Ratio p35/p25 ratio 24h after treatment (n=6 per group) (F) Ratio 
p-Tau(T205)/total Tau ratio 24h after treatment (n=6 per group). (G) GluA2 expression 24h 
after treatment (n=6 per group). (H) GluA2 surface/intracellular ratio 21 days post-treatment 
(n=6 per group). Results are expressed as mean ± SEM. *P<0.05 or ***P<0.001 compared with 
its corresponding saline group. 
18 
 
Fig 4: Effect of MDPV treatment on the expression of mRNA encoding G9a methyltransferase 
in VS 24h post-treatment (n=5 per group). Results are expressed as mean ± SEM. **P<0.01 vs 
saline group. 
Fig 5: Effect of MDPV treatment on the expression of factors related with dopaminergic 
transmission in DS: (A) D1R expression 24h (n=6 per group) and (B) 21 days after treatment 
(n=5 per group). (C) TH expression 24h (n=6 per group) and (D) 21 days after treatment (saline 
n=5 and MDPV n=5). (E) DAT density 24h (saline n=5 and MDPV n=6) and (F) 21 days after 
treatment (n=8 per group). DAT density was measured as [
3
H] WIN 35428 bound. Results are 
expressed as mean ± SEM. *P<0.05 or **P<0.01 compared with its corresponding saline 
group. 
Table 1:  Behavioral parameters registered in the OF test, both 3 and 21 days after treatment 
(saline n=7 and MDPV n=8). The corresponding F values of the two-way ANOVA analyses are 
shown below. *P<0.05 compared with saline W21 group or 
#
P<0.05 compared with MDPV W3 
group using Bonferroni post hoc test. 
Supplementary material 
Table S1: Commercial sources and dilution of primary and secondary antibodies used in the 
Western blot experiments. Brain region and time point of the measure are specified for each 
target.  
Table 1:  Behavioral parameters registered in the OF test, both 3 and 21 days after treatment. The corresponding F values of the two-way ANOVA analysis are shown below. *P<0.05 
compared with saline W21 group or 
#

















*P<0.05 vs saline W21; 
#
P<0.05 vs MDPV W3 
Treatment- withdrawal day Mean speed (cm/s) Locomotion (cm) 





to center (s) 
Entries in center 
Saline W3 
n=7 
5.57 ± 0.18 3343.72 ± 108.06 0.10 ± 0.014 29.02 ± 6.19 24.00 ± 3.09 
MDPV W3 
n=9 
5.40 ± 0.64 3098.83 ± 338.05 0.17 ± 0.02 6.72 ± 2.87 45.87 ± 8.37 
Saline W21 
n=7 
5.06 ± 0.29 3035.96 ± 171.56 0.16 ± 0.02 35.95 ± 16.31 




5.22 ± 0.76 3360.10 ± 418.18 0.26 ± 0.03 *
#
 6.13 ± 2.78
*
 60.87 ± 1.74
#
 
Two-way ANOVA analysis 
F (variable treatment (d.f.), P) 
Paired for t 
F (1, 13) = 0,0009408 
n.s. 
F (1, 13) = 0,008266 
n.s. 
F (1, 13) = 5,975 
P=0.0295 
F (1, 13) = 10.35 
P=0.0074 
F(1,13) = 4.203 
P=0.0611 
F (variable time (d.f.), P) 
Paired for t 
F (1, 13) = 0,2629 
n.s. 
F (1, 13) = 0,03724 
n.s. 
F (1, 13) = 27,59 
P=0.0002 
F (1, 13) = 0,1170 
n.s. 
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